Evidence map›Paper›PMID 40394553›Full record

ArticleBMC psychiatry2025

A retrospective analysis of vortioxetine utilization in children and adolescents with major depressive disorder in clinical practice.

Xianmei Luo, Shu Yu, Keliang Pan, Lin Cheng, Fan Luo, Handi Zhang, Mingjun Duan, Yajun Zhang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Xianmei LuoMOE Key Lab for Neuroinformation, The Clinical Hospital of Chengdu Brain Science Institute, University of Electronic Science and Technology of China, Chengdu, 611731, China.
Shu YuMOE Key Lab for Neuroinformation, The Clinical Hospital of Chengdu Brain Science Institute, University of Electronic Science and Technology of China, Chengdu, 611731, China.
Keliang PanMOE Key Lab for Neuroinformation, The Clinical Hospital of Chengdu Brain Science Institute, University of Electronic Science and Technology of China, Chengdu, 611731, China.
Lin ChengMOE Key Lab for Neuroinformation, The Clinical Hospital of Chengdu Brain Science Institute, University of Electronic Science and Technology of China, Chengdu, 611731, China.
Fan LuoMOE Key Lab for Neuroinformation, The Clinical Hospital of Chengdu Brain Science Institute, University of Electronic Science and Technology of China, Chengdu, 611731, China.
Handi ZhangMental Health Center of Shantou University, Shantou, 515000, China.
Mingjun DuanMOE Key Lab for Neuroinformation, The Clinical Hospital of Chengdu Brain Science Institute, University of Electronic Science and Technology of China, Chengdu, 611731, China. fourhospital@163.com.
Yajun ZhangMOE Key Lab for Neuroinformation, The Clinical Hospital of Chengdu Brain Science Institute, University of Electronic Science and Technology of China, Chengdu, 611731, China. 13509878261@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTreating depression in children and adolescents has always been a challenge in clinical pharmacotherapy. Vortioxetine, as a new type of antidepressant, is considered to have the potential for use in the treatment of depression in children and adolescents. This study aimed to evaluate the usage of vortioxetine and its efficacy and tolerability in children and adolescents with major depressive disorder in a real-world study.

methodsA retrospective survey of vortioxetine treatment was conducted at a Class A tertiary mental health hospital. Data regarding the demographic and clinical characteristics were collected among children and adolescents with major depressive disorder from electronic medical record system.

resultsThe study included a total of 253 depressive patients, comprising 96 males and 157 females, who were prescribed vortioxetine at any time during the research period. One hundred and twenty-three patients (43.62%) received vortioxetine treatment at the initial visit. Of the total patients, 27 (10.67%) reported side effect, such as nausea, vomiting, dizziness, palpitations, diarrhea, drowsiness, and itching. Additionally, 20 (7.91%) discontinued medical treatment due to adverse effect. No significant difference was found between males and females in drug-related adverse events (X

conclusionThere exists a certain proportion of children and adolescents suffering from depression who are prescribed vortioxetine in an off-label manner in psychiatric clinics. Vortioxetine demonstrates well tolerability in clinical practice. However, the proportion of self-report symptom alleviation is comparatively unsatisfactory. Furthermore, gender appears influence on self-report symptom relief.

Indexed as

Antidepressive AgentsMajor Depressive DisorderVortioxetineAdolescentChildFemaleHumansMaleRetrospective StudiesAntidepressive AgentsVortioxetineAdolescentsChildrenMajor depressive disorderRetrospective analysisVortioxetine

Identifiers

PMID40394553
PMCPMC12093813

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.